Stockreport

Why Analysts Are Rethinking Roivant Sciences After Strong Phase 3 Results and Analyst Upgrades [Yahoo! Finance]

Roivant Sciences Ltd.  (ROIV) 
PDF rising from $18.30 to $20.05 after the release of strong Phase 3 dermatomyositis data. This upward revision highlights growing optimism around the company's recent clini [Read more]